Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: A 13-year experience in Iran

International Journal of Hematology

Volumn 95, Issue 1, 2012, Pages 51-56

  Karimi, Mehran ^a   Haghpanah, Sezaneh ^a   Farhadi, Ali ^a   Yavarian, Majid ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

thalassemia; Hydroxyurea; Mutations; Transfusion

Indexed keywords

BETA GLOBIN; HYDROXYUREA;

ADULT; BETA THALASSEMIA; BLOOD TRANSFUSION; CONFERENCE PAPER; DNA POLYMORPHISM; FEMALE; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PHENOTYPE; SKIN DISEASE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIMETABOLITES; BETA-GLOBINS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HUMANS; HYDROXYUREA; IRAN; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SITE-SPECIFIC DNA-METHYLTRANSFERASE (ADENINE-SPECIFIC); YOUNG ADULT;

EID: 84857633493     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0985-6     Document Type: Conference Paper

References (29)

1. M Karimi M Yavarian A Afrasiabi J Dehbozorgian E Rachmilewitz 2008 Prevalence of beta-thalassemia trait and glucose-6-phosphate dehydrogenase deficiency in Iranian Jews Arch Med Res 39 212 214 18164966 10.1016/j.arcmed. 2007.09.001 1:CAS:528:DC%2BD1cXhtlCiuw%3D%3D (Pubitemid 350299616)
2. A Kattamis 2007 Treatment of thalassemia with hydroxyurea: an indispensable alternative therapy J Pediatr Hematol Oncol 29 729 730 17984687 10.1097/MPH.0b013e3181583b46 (Pubitemid 350071217)
3. M Bradai MT Abad S Pissard F Lamraoui L Skopinski M de Montalembert 2003 Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia Blood 102 1529 1530 12702505 10.1182/blood-2003-01-0117 1:CAS:528:DC%2BD3sXmsFWktb4%3D (Pubitemid 36988066)
4. C Hoppe E Vichinsky B Lewis D Foote L Styles 1999 Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia Am J Hematol 62 221 227 10589077 10.1002/(SICI)1096-8652(199912)62:4<221::AID-AJH4>3.0.CO;2-R 1:CAS:528:DC%2BD3cXhsVagsQ%3D%3D
5. M Karimi 2009 Hydroxyurea in the management of thalassemia intermedia Hemoglobin 33 Suppl 1 S177 S182 20001623 10.3109/03630260903351809 1:CAS:528:DC%2BD1MXhsFGrurvP
6. A Koren C Levin O Dgany T Kransnov R Elhasid L Zalman, et al. 2008 Response to hydroxyurea therapy in beta-thalassemia Am J Hematol 83 366 370 18181203 10.1002/ajh.21120 1:CAS:528:DC%2BD1cXmvVSgtro%3D (Pubitemid 351614748)
7. M Yavarian M Karimi E Bakker CL Harteveld PC Giordano 2004 Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients Haematologica. 89 1172 1178 15477200 1:CAS:528:DC%2BD2cXhtVGjsrrO (Pubitemid 39390440)
8. M Bradai S Pissard MT Abad A Dechartres JA Ribeil P Landais, et al. 2007 Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia Transfusion. 47 1830 1836 17880608 10.1111/j.1537-2995.2007.01399.x 1:CAS:528:DC%2BD2sXht1elsrvE (Pubitemid 47438549)
9. MA Ehsani AA Hedayati-Asl A Bagheri S Zeinali A Rashidi 2009 Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature Pediatr Hematol Oncol 26 560 565 19954365 10.3109/08880010903271671 1:CAS:528: DC%2BD1MXhsFSqtLfM
10. FM Hajjar HA Pearson 1994 Pharmacologic treatment of thalassemia intermedia with hydroxyurea J Pediatr 125 490 492 7520935 10.1016/S0022-3476(05) 83304-9 1:STN:280:DyaK2czltFCntA%3D%3D (Pubitemid 24291887)
11. M Karimi H Darzi M Yavarian 2005 Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran J Pediatr Hematol Oncol 27 380 385 16012328 10.1097/01.mph.0000174386.13109.28 (Pubitemid 41077027)
12. D Loukopoulos E Voskaridou A Stamoulakatou Y Papassotiriou V Kalotychou A Loutradi, et al. 1998 Hydroxyurea therapy in thalassemia Ann N Y Acad Sci 850 120 128 9668534 10.1111/j.1749-6632.1998.tb10469.x 1:CAS:528:DyaK1cXkslOrsbc%3D (Pubitemid 28369753)
13. YT Zeng SZ Huang ZR Ren ZH Lu FY Zeng AN Schechter, et al. 1995 Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis Br J Haematol 90 557 563 7646994 10.1111/j.1365-2141.1995.tb05584.x 1:STN:280: DyaK2MznsV2jtg%3D%3D
14. M Alebouyeh F Moussavi H Haddad-Deylami P Vossough 2004 Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening Ann Hematol 83 430 433 14722738 10.1007/s00277-003-0836-5 1:CAS:528: DC%2BD2cXksFSisrw%3D (Pubitemid 38877964)
15. H Cario M Wegener KM Debatin E Kohne 2002 Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis Ann Hematol 81 478 482 12224008 10.1007/s00277-002-0501-4 1:STN:280:DC%2BD38vmsVSgsw%3D%3D (Pubitemid 36067664)
16. EV de Paula CS Lima VR Arruda FL Alberto ST Saad FF Costa 2003 Long-term hydroxyurea therapy in beta-thalassaemia patients Eur J Haematol 70 151 155 12605659 10.1034/j.1600-0609.2003.00037.x (Pubitemid 36606075)
17. SZ Huang ZR Ren MJ Chen HP Xu YT Zeng GP Rodgers, et al. 1994 Treatment of beta-thalassemia with hydroxyurea (HU)-effects of HU on globin gene expression Sci China B 37 1350 1359 7865126 1:STN:280:DyaK2M7mvFaltQ%3D%3D
18. M Kosaryan K Vahidshahi H Karami S Ehteshami 2009 Effect of hydroxyurea on thalassemia major and thalassemia intermedia in Iranian patients Pak J Med Sci 25 74 78
19. A Dixit TC Chatterjee P Mishra DR Choudhry M Mahapatra S Tyagi, et al. 2005 Hydroxyurea in thalassemia intermedia-a promising therapy Ann Hematol 84 441 446 15838670 10.1007/s00277-005-1026-4 1:CAS:528:DC%2BD2MXkvVCksrg%3D (Pubitemid 40867920)
20. A Taher M Sheikh-Taha 2006 Hydroxyurea use in Lebanese patients with beta-thalassemia intermedia J Pediatr Hematol Oncol 28 107 16462586 10.1097/01.mph.0000200671.39549.2b
21. M Karimi N Cohan K Moosavizadeh MJ Falahi S Haghpanah 2010 Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience Pediatr Hematol Oncol 27 205 211 20367264 10.3109/08880011003639952 1:CAS:528:DC%2BC3cXkt1Grsbs%3D
22. O Zargari A Kimyai-Asadi M Jafroodi 2004 Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia Pediatr Dermatol 21 633 635 15575845 10.1111/j.0736-8046.2004.21603.x (Pubitemid 39657384)
23. EE O'Branski RE Ware NS Prose TR Kinney 2001 Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy J Am Acad Dermatol. 44 859 861 11312437 10.1067/mjd.2001.113471 (Pubitemid 32391177)
24. BJ Kennedy LR Smith RW Goltz 1975 Skin changes secondary to hydroxyurea therapy Arch Dermatol 111 183 187 1054261 10.1001/archderm.1975.01630140041002 1:STN:280:DyaE2M7gsl2hsQ%3D%3D
25. M de Montalembert P Begue F Bernaudin I Thuret D Bachir M Micheau 1999 Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease Arch Dis Child. 81 437 439 10519721 10.1136/adc.81.5.437 (Pubitemid 29501380)
26. C Borgna-Pignatti 2007 Modern treatment of thalassaemia intermedia Br J Haematol 138 291 304 17565568 10.1111/j.1365-2141.2007.06654.x 1:CAS:528:DC%2BD2sXpsVClt70%3D (Pubitemid 47035387)
27. BR Saxon JS Waye NF Olivieri 1998 Increase in hemoglobin concentration during therapy with hydroxyurea in Cooley's anemia Ann N Y Acad Sci 850 459 460 9668583 10.1111/j.1749-6632.1998.tb10520.x 1:STN:280:DyaK1czjtlWrsg%3D%3D (Pubitemid 28369803)
28. KY Italia FJ Jijina R Merchant S Panjwani AH Nadkarni PM Sawant, et al. 2009 Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India Clin Chim Acta. 407 10 15 19545554 10.1016/j.cca.2009.06.019 1:CAS:528:DC%2BD1MXpt1KisL8%3D
29. I Panigrahi A Dixit S Arora M Kabra M Mahapatra VP Choudhry, et al. 2005 Do alpha deletions influence hydroxyurea response in thalassemia intermedia? Hematology. 10 61 63 16019448 10.1080/10245330400020439 1:CAS:528: DC%2BD2MXjvVOksL4%3D (Pubitemid 41093591)